fda glp-1 compounding crackdown september 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA ramps up its pushback

injection-site reactions occur with the weekly subcutaneous formulations

An Analytical Study Based on Post-Marketing Approval Pharmacovigilance Data. Frontiers in Endocrinology, vol

A detailed description of the recruitment process and collection of phenotypic data by the QGP and the QBB was previously reported 76

GLP-1 receptors the docking points where GLP-1 attaches and delivers its message are found not just in the pancreas, but also in specific regions of the brain that control hunger, fullness, and food cravings

When to Discontinue Therapy Not every rash requires stopping treatment

The goal shouldn't be to lose weight it should be to lose fat while preserving (or building) muscle